5-FU and Fruquintinib for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced colorectal cancer that cannot be surgically removed or has spread to other parts of your body.
- You have not had any chemotherapy for your cancer before.
- You are able to swallow pills.
- You are in good overall health with an ECOG performance status of 0 or 1.
- Your organ function (blood counts, liver, kidneys) must be within normal limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This study tests a combination of three drugs—fruquintinib (an anti-angiogenic agent), serplulimab (an immune-boosting antibody), and standard chemotherapy—as a first-line treatment for advanced colorectal cancer with specific genetic mutations. The goal is to see if this combination can help shrink or control tumors better than standard treatment alone.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a drug called fruquintinib for people with advanced colorectal cancer that has spread. It is for patients who have already tried several standard treatments and need a new option.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.